Portage Biotech Future Growth

Future criteria checks 0/6

Portage Biotech is forecast to grow earnings at 77.8% per annum. EPS is expected to grow by 89.7% per annum.

Key information

77.8%

Earnings growth rate

89.7%

EPS growth rate

Biotechs earnings growth	24.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	11 Mar 2024

Recent future growth updates

Recent updates

Portage Biotech GAAP EPS of -$0.13

Aug 29

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Jul 20

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Jul 06

Earnings and Revenue Growth Forecasts

NasdaqCM:PRTG - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	N/A	-18	N/A	N/A	1
3/31/2025	N/A	-16	N/A	N/A	1
3/31/2024	N/A	-52	N/A	N/A	2
12/31/2023	N/A	-145	-16	-16	N/A
9/30/2023	N/A	-113	-15	-15	N/A
6/30/2023	N/A	-109	-13	-13	N/A
3/31/2023	N/A	-105	-12	-12	N/A
12/31/2022	N/A	-17	-10	-10	N/A
9/30/2022	N/A	-14	-9	-9	N/A
6/30/2022	N/A	-16	-7	-7	N/A
3/31/2022	N/A	-17	-7	-7	N/A
12/31/2021	N/A	-21	-5	-5	N/A
9/30/2021	N/A	-19	-5	-5	N/A
6/30/2021	N/A	-18	-5	-5	N/A
3/31/2021	N/A	-16	-4	-4	N/A
12/31/2020	N/A	-6	-4	-4	N/A
9/30/2020	N/A	-6	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-5	-3	-3	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-3	-1	-1	N/A
12/31/2018	N/A	124	-1	-1	N/A
9/30/2018	N/A	124	-1	-1	N/A
6/30/2018	N/A	124	-1	-1	N/A
3/31/2018	N/A	124	-1	-1	N/A
12/31/2017	N/A	-10	2	2	N/A
9/30/2017	N/A	-16	N/A	2	N/A
6/30/2017	N/A	19	N/A	2	N/A
3/31/2017	N/A	16	N/A	-1	N/A
12/31/2016	N/A	24	N/A	-6	N/A
9/30/2016	N/A	27	N/A	-7	N/A
6/30/2016	N/A	-8	N/A	-8	N/A
3/31/2016	N/A	-6	N/A	-6	N/A
12/31/2015	N/A	-6	N/A	-6	N/A
9/30/2015	N/A	-3	N/A	-5	N/A
6/30/2015	N/A	-3	N/A	-3	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-3	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRTG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRTG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PRTG's revenue is forecast to grow faster than the US market.

High Growth Revenue: PRTG is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PRTG's Return on Equity is forecast to be high in 3 years time

Portage Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 16% to US$16.00

Recent updates

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc.

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC

Portage Biotech Inc. announced that it has received $6.98145 million in funding

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies